Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial.

Fertil Steril

Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, Virginia; Virginia Fertility and IVF, Charlottesville, Virginia. Electronic address:

Published: May 2024

AI Article Synopsis

  • The study aimed to compare the effectiveness of medroxyprogesterone acetate (MPA) for ovulatory suppression during in vitro fertilization (IVF) against traditional gonadotropin-releasing hormone (GnRH) antagonist cycles.
  • It included a cohort of 418 patients treated with MPA and 419 patients in a historical control group, with findings indicating no premature ovulation in the MPA group compared to five cases in the control group.
  • Although there were no significant differences in oocyte or embryo quality, the MPA group experienced lower medication costs, fewer monitoring visits, and less injection frequency during the IVF process.

Article Abstract

Objective: To broadly assess the efficacy of medroxyprogesterone acetate (MPA) for ovulatory suppression during in vitro stimulation compared with gonadotropin-releasing hormone (GnRH) antagonist cycles.

Design: Cohort trial.

Setting: A single academic-affiliated private fertility practice.

Patients: Patients of all diagnoses aged 18-44 years undergoing autologous in vitro fertilization (IVF) for fertility treatment between 2020 and 2023.

Interventions: Comparison of MPA vs. antagonist IVF stimulation cycles.

Main Outcome Measures: Rates of premature ovulation, oocyte and embryo yield, embryo quality, pregnancy rates, and logistical benefits.

Results: Prospective data was collected on 418 patients who underwent MPA protocol ovarian stimulation (MPA group), which was compared with 419 historical control gonadotropin hormone-releasing hormone antagonist cycles (control group). Age was similar between groups (35.6 ± 4.6 vs. 35.7 ± 4.8 years; P = .75). There were no cases of premature ovulation in the MPA group compared with a total of five cases in the control group (0% vs. 1.2%; risk ratio [RR] = 0.09; 95% confidence interval [CI], 0.01, 1.66). No differences were seen between number of oocytes retrieved (14.3 ± 10.2 vs. 14.3 ± 9.7; P = .83), blastocysts (4.9 ± 4.6 vs. 5.0 ± 4.6; P = .89), or euploid blastocysts (2.4 ± 2.6 vs. 2.2 ± 2.4; P = .18) in the MPA vs. control group respectively. Clinical pregnancy rate was similar between groups (70.4% vs. 64.2%; RR = 0.92; 95% CI, 0.72, 1.18). There was no difference in length of IVF stimulation or dose of stimulation medications. Patients in the MPA group saved an average of $491 ± $119 on medications, had an average of one less monitoring visit (4.4 ± 0.9 vs. 5.6 ± 1.1; P<.01), and 5.0 ± 1.2 less injections per cycle. When adjusting for age and ovarian reserve, protocol group (MPA vs. control) did not influence having an embryo available for transfer (76.6% vs. 73.4%; adjusted RR = 1.05; 95% CI, 0.94, 1.14).

Conclusion: For ovulatory suppression during IVF cycles, MPA was effective at preventing ovulation while demonstrating similar cycle and reproductive outcomes, with the additional benefits of patient cost savings, increased convenience with decreased number of visits, and fewer injections.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fertnstert.2024.01.026DOI Listing

Publication Analysis

Top Keywords

mpa group
12
control group
12
medroxyprogesterone acetate
8
ivf stimulation
8
premature ovulation
8
group compared
8
mpa
7
group
6
stimulation
5
oral medroxyprogesterone
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!